Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Functional Brands, Inc. Common Stock (MEHA)
Lake Oswego, US
Functional Brands, Inc. is a U.S.-based company that produces and supplies a comprehensive range of nutraceutical supplements. Its product portfolio targets a broad spectrum of health and wellness needs, encompassing categories like pain management, energy enhancement, prenatal support, general well-being, bone and joint health, gastrointestinal function, immunity, cardiac care, detoxification, cognitive support, sleep aids, and urinary health. In addition to its core nutraceutical offerings, the company also provides a line of hemp-derived products, available in convenient forms such as capsules, gummies, and tinctures.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.35% | -46.14% | -28.50% | -57.10% | -76.89% | -54.65% | -96.88% | -96.88% | -96.88% | -96.88% | -96.88% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Distribution: +5.6%+0.7% Q1'26: +3.5% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%+112.0% ★ Q1'26: -1,867.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%-15.1% Q1'26: -25.8% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%+1,171.4% Q1'26: +183.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×-1.34× Q1'26: -0.65× (vs Q1'25)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-13 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 1/5 | 5/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Eric Gripentrog | Chairman & CEO | 586.7K | male |
| Tariq Rahim | Chief Financial Officer, Principal Accounting Officer & Director | 200.0K | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MEHA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
